COVID 19 Therapeutic Pipeline Vaccines and Diagnostics Competitive Landscape 2020

First identified in Hubei province of Wuhan, China, this is the third time the coronavirus has created havoc in the whole world. Coronaviruses (CoV) are a large family of viruses that cause illnesses ranging from the common cold to more severe diseases such as Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV). Known initially as novel coronavirus-2019 (nCoV-19), the virus has now been named Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the International Committee on Taxonomy of Viruses (ICTV), due to its genetic similarity with the coronavirus responsible for 2003 SARS outbreak.

It has already spread to more than 160 countries all over Asia, Europe, North America and the Middle East. More than 250k have been confirmed positive with SARS-CoV-2 as on March 20th, 2020. Looking at the rapid transmission of the infection and gravity of the situation, on 11th March 2020, the World Health Organization (WHO) declared the coronavirus outbreak a pandemic.

Get sample copy of "COVID 19 Market" at: https://www.premiummarketinsights.com/sample/DELV00026265

COVID 19 Overview

This comprehensive report offers a solid foundation to start - or progress - further research and analysis into the COVID 19, including causes and symptoms, morbidity and mortality to transmission, treatment and prevention.

COVID 19 is a respiratory viral infection, in which common signs of infection include respiratory symptoms, fever, and cough, shortness of breath and breathing difficulties. In more severe cases, the infection can cause pneumonia, severe acute respiratory syndrome, kidney failure and even death.

The recent report by Publisher outlays comprehensive insights of present clinical development scenario and growth prospects across the COVID- 19 pipeline. A detailed picture of the COVID-19pipeline landscape is provided, which includes the disease overview and COVID-19treatment guidelines specific to the country. The assessment part of the report elucidates in-depth COVID 19 clinical assessment of the COVID-19pipeline products from the pre-clinical developmental phase to the advanced phase.

In COVID-19report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, along with COVID 19 collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Have any query? Enquire about report at: https://www.premiummarketinsights.com/sample/DELV00026265

COVID-19Screening and Diagnosis

On the precautionary side of the efforts, temperature screening of travelers on various airports is conducted to prevent further spread of the virus. In many countries, incoming passengers are even being screened for fever, cough, and shortness of breath. Any traveler with signs or symptoms of illness is receiving a more comprehensive public health assessment. WHO has urged the nations to speed up their diagnosing and testing of the virus to contain the spread of coronavirus as more governments impose lockdown or stop travel. In an effort to provide efficient diagnosis, the FDA granted an Emergency Use Authorization to its first commercially developed coronavirus test developed by Roche (Cobas SARS-CoV-2 Test).

Roche has begun the shipments of first 400,000 COVID 19 tests to laboratories across the USA to begin patient testing under FDA Emergency Use Authorization. FDA has also approved the use of Thermo Fisher's TaqPath COVID 19 Combo Kit. BioMedomics is working to deploy its COVID-19IgM-IgG Rapid Test, an immunoassay that can yield results from a blood sample in 15 minutes at the point of care. The report covers the detailed analysis of all the diagnostic kits in the development phase. Chinese government has given its green signal to a 29-minute rapid testing kit for COVID-19which has been developed by Xiamen University and approved by National Medical Products Administration.

Buy this Report Now at: https://www.premiummarketinsights.com/buy/DELV00026265

Scope of the Report

- The report builds an understanding of the technologies and techniques being used to develop -COVID 19 treatment drugs and vaccines.

- Comprehensive insights into the pipeline products. The report provides detailed profiles of the

pipeline assets and comparative analysis of clinical and non-clinical stage products.

- Assessment of active pipeline assets segmented by stage, product type, route of administration and molecule type

- The report builds understanding of the insights about the pipeline drugs including the product-related agreements, collaborations, licensing, deals and technology

- The -COVID 19 report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for -COVID 19 across the complete product development cycle, including all clinical and nonclinical stages.

- The companies and academics are working to assess challenges and seek opportunities that could influence COVID 19 R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

- A detailed assessment of the diagnostic tests being developed for the diagnosis of COVID 19 infection, providing information on test developer(s), development geography, technology being used in the test, time to result, and, test sample type.

- The report covers key strategies by major players in drug development with their clinical trial information, key and ongoing trends, potential market driver & barriers, and opportunities to curate best of the assess underlying potential of the market.

Contact Us:
Call: +912067274191
Email: sales@premiummarketinsights.com

About Premiummarketinsights:

Premiummarketinsights.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

This release was published on openPR.